Research programme: antipsychotic therapeutics - Pfizer

Drug Profile

Research programme: antipsychotic therapeutics - Pfizer

Alternative Names: Compound 22; WAY-162545; WAY-163909; WAY-261240; WAY-629

Latest Information Update: 27 Sep 2011

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Chromans; Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Psychotic disorders

Most Recent Events

  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 20 Aug 2009 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Schizophrenia presented at the 238th National Meeting of the American Chemical Society (238th-ACS-2009) ,
  • 16 Aug 2009 Preclinical trials in Psychotic disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top